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A small peptide antagonist of the Fas
receptor inhibits neuroinflammation and
prevents axon degeneration and retinal
ganglion cell death in an inducible mouse
model of glaucoma
Anitha Krishnan1, Andrew J. Kocab2, David N. Zacks3, Ann Marshak-Rothstein4 and Meredith Gregory-Ksander1*
Abstract
Background: Glaucoma is a complex, multifactorial disease where apoptosis, microglia activation, and inflammation
have been linked to the death of retinal ganglion cells (RGCs) and axon degeneration. We demonstrated previously
that FasL-Fas signaling was required for axon degeneration and death of RGCs in chronic and inducible mouse
models of glaucoma and that Fas activation triggered RGC apoptosis, glial activation, and inflammation. Here, we
investigated whether targeting the Fas receptor with a small peptide antagonist, ONL1204, has anti-inflammatory
and neuroprotective effects in a microbead-induced mouse model of glaucoma.
Methods: Intracameral injection of microbeads was used to elevate intraocular pressure (IOP) in Fas-deficient
(Faslpr) mice and WT C57BL/6J mice that received an intravitreal injection of the Fas inhibitor, ONL1204 (2 μg/1 μl)
(or vehicle only), on day 0 or day 7 after microbead injection. The IOP was monitored by rebound tonometry, and
at 28 days post-microbead injection, Brn3a-stained RGCs and paraphenylenediamine (PPD)-stained axons were
analyzed. The effects of ONL1204 on retinal microglia activation and the expression of inflammatory genes were
analyzed by immunostaining of retinal flatmounts and quantitative PCR (qPCR).
Results: Rebound tonometry showed equivalent elevation of IOP in all groups of microbead-injected mice. At 28
days post-microbead injection, the RGC and axon counts from microbead-injected Faslpr mice were equivalent to
saline-injected (no IOP elevation) controls. Treatment with ONL1204 also significantly reduced RGC death and loss
of axons in microbead-injected WT mice when compared to vehicle-treated controls, even when administered after
IOP elevation. Confocal analysis of Iba1-stained retinal flatmounts and qPCR demonstrated that ONL1204 also
abrogated microglia activation and inhibited the induction of multiple genes implicated in glaucoma, including
cytokines and chemokines (GFAP, Caspase-8, TNFα, IL-1β, IL-6, IL-18, MIP-1α, MIP-1β, MIP-2, MCPI, and IP10),
components of the complement cascade (C3, C1Q), Toll-like receptor pathway (TLR4), and inflammasome pathway
(NLRP3).
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Conclusions: These results serve as proof-of-principal that the small peptide inhibitor of the Fas receptor, ONL1204,
can provide robust neuroprotection in an inducible mouse model of glaucoma, even when administered after IOP
elevation. Moreover, Fas signaling contributes to the pathogenesis of glaucoma through activation of both
apoptotic and inflammatory pathways.
Keywords: Glaucoma, Neuroprotection, Retinal ganglion cell, Fas ligand, Fas receptor, Apoptosis,
Neuroinflammation, Neurodegeneration, Microglia, Immune privilege,
Background
Glaucoma is the leading cause of irreversible blindness
worldwide, characterized by the progressive loss of ret-
inal ganglion cells (RGCs). A recent study estimates that
approximately 60 million people worldwide currently
suffer from glaucoma, and with the rapidly growing
aging population, this number is predicted to exceed 100
million by 2040 [1]. Elevated intraocular pressure (IOP)
is a major risk factor for the development of glaucoma,
and lowering IOP remains the only treatment for this
disease [2]. However, the continued progression of the
disease in some patients despite successful reduction of
IOP [3], combined with the increasing incidence of
normal-tension glaucoma [4, 5] and the absence of neu-
rodegeneration in some patients with elevated IOP [6],
indicates that IOP-independent mechanisms contribute
to the initiation and progression of glaucoma. Therefore,
a current priority in the glaucoma field is to further de-
fine the molecular mechanisms of RGC death and axon
degeneration in order to develop IOP-independent
therapeutic treatment strategies to halt disease progres-
sion and preserve vision.
There is substantial evidence that apoptosis of RGCs is
the final common pathway in both human and experimen-
tal models of glaucoma [7–10]. However, using the DBA/2J
mouse model of spontaneous glaucoma, Libby et al. dem-
onstrated that genetic ablation of the proapoptotic mol-
ecule BCL2-associated X protein (BAX) prevents apoptosis
of RGCs, but does not prevent axon degeneration [11].
Similarly, McKinnon et al. demonstrated that gene therapy
with a potent caspase inhibitor, baculoviral IAP repeat-
containing protein-4 (BIRC4), only protects about 50% of
the RGCs and optic nerve axons in a rodent model of ele-
vated IOP [12]. Therefore, while RGC apoptosis is the com-
mon endpoint in glaucoma, therapeutic approaches that
only target the apoptotic pathway in RGCs do not com-
pletely prevent glaucomatous neurodegeneration.
Glaucoma is a complex multifactorial disease, and
while the exact molecular mechanisms of RGC apop-
tosis are not completely understood, there is growing
evidence that suggests microglia activation and neuro-
inflammation play a central role in both early and late
stages of glaucomatous neurodegeneration [13–16]. In
human and experimental models of glaucoma, acti-
vated microglia are detected in the optic nerve head
(ONH) and retina [14–19] and the extent of microglia
activation correlates with the extent of neurodegenera-
tion [20, 21]. Moreover, blocking microglia activation
with minocycline [14, 20] or anti-TNFα [22, 23] pre-
vents the infiltration of immune cells and significantly
reduces axon degeneration and death of RGCs in ex-
perimental models of glaucoma. Together, these data
suggest that activated microglia are the driving force
behind glaucomatous neurodegeneration. However,
the molecular mechanism(s) that mediate microglia
reactivity in glaucoma are not well understood.
Fas ligand (FasL) is a type II transmembrane protein of
the TNF family, which is best known for its ability to in-
duce apoptosis upon binding to the Fas receptor [24–27].
However, we demonstrated that within the eye, FasL can be
expressed as a membrane-bound protein (mFasL), which is
pro-apoptotic and pro-inflammatory, or it can be cleaved
and released as a soluble isoform (sFasL), which is non-
apoptotic and non-inflammatory [28–30]. In the normal
immune-privileged eye, where inflammation is tightly regu-
lated, FasL is primarily expressed as the non-apoptotic,
non-inflammatory sFasL [31]. However, in the DBA/2J
mouse model of glaucoma, a shift in the expression of FasL
from the soluble form to the proapoptotic and proinflam-
matory membrane form coincides with the loss of immune
privilege and the development of glaucoma [31, 32]. These
data suggest mFasL activation of the Fas receptor plays a
central role in the pathogenesis of glaucoma. Moreover,
treating mice with sFasL, via intravitreal adeno-associated
virus-mediated gene delivery, provided significant neuro-
protection of RGCs and axons, and this protection corre-
lated with inhibition of retinal glial activation and the
induction of the proinflammatory mediators [31]. These
data demonstrate that blocking mFasL activation of the Fas
receptor inhibits three hallmarks of glaucomatous degener-
ation: microglia activation, inflammation, and apoptosis.
Therefore, we hypothesized that specifically blocking the
Fas receptor with a small peptide inhibitor could serve as a
novel neuroprotective approach in the treatment of
glaucoma.
When developing a small peptide inhibitor of Fas, we
first looked into the reports that Met, a growth factor
receptor tyrosine kinase, could directly bind to and se-
quester the Fas receptor in hepatocytes [33]. This se-
questration of the Fas receptor prevents Fas activation
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and subsequent apoptosis, identifying Met as an inhibi-
tor of the Fas pathway. Using this information, we de-
veloped Met12, which is a small peptide that inhibits
Fas-induced caspase-8 activation in the 661W photo-
receptor cell line [34], for ocular use. In vivo, Met12
significantly inhibited photoreceptor apoptosis in a
mouse model of retinal detachment [34]. More recently,
we demonstrated that Met12 also inhibits Fas activation
and subsequent apoptosis of photoreceptors and RPE in
a sodium iodate-induced mouse model of retinal degen-
eration [35]. Together, these studies demonstrate that
Met12 can be used in vivo to inhibit Fas-mediated
apoptosis in models of retinal injury and degeneration.
Herein, we used a well-defined microbead-induced
mouse model of elevated IOP to (i) examine the ability
of a new derivative of Met12, ONL1204, to protect
RGCs and prevent axon degeneration, and (ii) test the
hypothesis that the Fas signaling pathway mediates
microglia activation and the induction of neurodestruc-
tive inflammation in glaucoma. Our results demonstrate
that a single intravitreal administration of the Fas inhibi-
tor, ONL1204, significantly reduced RGC death and
axon degeneration, even when administered after ele-
vated IOP. Moreover, the neuroprotection correlated
with significant inhibition of retinal microglia activation
and inflammatory genes expression, suggesting that Fas
signaling contributes to the pathogenesis of glaucoma
through both apoptotic and inflammatory pathways. To-
gether, these data underscore the value of targeting Fas
in glaucoma and provide proof-of-principal that the
small peptide inhibitor of the Fas receptor, ONL1204,
can provide robust neuroprotection in an inducible
mouse model of glaucoma, even when administered after
elevated IOP.
Materials and methods
Animals
All animal experiments were approved by the Institu-
tional Animal Care and Use Committee at Schepens Eye
Research Institute and were performed under the guide-
lines of the Association of Research in Vision and Oph-
thalmology (Rockville, MD). The 8-week-old C57BL/6J
WT mice (Stock No: 000664) and B6.MRL-Faslpr/J Fas
receptor-deficient mice (Stock No: 000482) were pur-
chased from Jackson Laboratories (Bar Harbor, ME) and
housed and maintained under cyclic light (12 L-30 lux:
12D) conditions in an AAALAC-approved animal facility
at the Schepens Eye Research Institute. To avoid sex
bias, equal numbers of male and female mice were in-
cluded in each experimental group.
Microbead-induced model of elevated IOP
Mice were anesthetized by intraperitoneal injection of a
mixture of ketamine (100 mg/kg; Ketaset; Fort Dodge
Animal Health, Fort Dodge, IA) and xylazine (9 mg/kg;
TranquiVed; Vedco, Inc., St. Joseph, MO) supple-
mented by topical application of proparacaine (0.5%;
Bausch & Lomb, Tampa, FL). Elevation of IOP was in-
duced unilaterally by injection of polystyrene microbe-
ads (FluoSpheres; Invitrogen, Carlsbad, CA; 15-μm
diameter) into the anterior chamber of the right eye of
each animal under a surgical microscope, as previously
reported [31]. Briefly, microbeads were prepared at a
concentration of 5.0 × 106 beads/ml in sterile physio-
logic saline. The right cornea was gently punctured
near the center using a sharp glass micropipette (World
Precision Instruments Inc., Sarasota, FL). A small vol-
ume (2 μL) of microbeads was injected through this
preformed hole into the anterior chamber followed by
injection of an air bubble via the micropipette con-
nected with a Hamilton syringe. Any mice that devel-
oped signs of inflammation (clouding of the cornea,
edematous cornea, etc.) were excluded from the study.
IOP measurements
IOP was measured with a rebound TonoLab tonometer
(Colonial Medical Supply, Espoo, Finland), as previously
described [31, 33]. Mice were anesthetized by 3% isoflur-
ane in 100% oxygen (induction) followed by 1.5% isoflur-
ane in 100% oxygen (maintenance) delivered with a
precision vaporizer. IOP measurement was initiated
within 2 to 3 min after animals lost toe pinch reflex or
tail pinch response. Anesthetized mice were placed on a
platform, and the tip of the pressure sensor was placed
approximately 1/8 in. from the central cornea. Average
IOP was displayed automatically after six measurements
after elimination of the highest and lowest values. This
machine-generated mean was considered as one reading,
and six readings were obtained for each eye. All IOPs
were taken at the same time of day (between 10:00 and
12:00 h) due to the variation of IOP throughout the day.
Intravitreal injections
The intravitreal injections, just posterior to the limbus
and parallel to the conjunctival vessels, were performed
as previously described [31, 36]. Mice received a 1-μl in-
travitreal injection containing ONL1204 (2 mg/ml) or
vehicle control on day 0 (just prior to injection of
microbeads) or day 7 after microbeads injection.
Quantification of optic nerve axons
For quantification of axons, optic nerves were dissected and
fixed in Karnovsky’s reagent (50% in phosphate buffer)
overnight. Semi-thin cross-sections of the nerve were taken
at 1.0mm posterior to the globe and stained with 1% p-
phenylenediamine (PPD) for evaluation by light micros-
copy. Ten non-overlapping photomicrographs were taken
at × 100 magnification covering the entire area of the optic
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nerve cross-section. Using ImageJ software, a 50 μM×
50 μM square was placed on each × 100 image and all
axons within the square (0.0025 mm2) were counted using
the threshold and analyze particles function in image J as
previously described [31]. The average axon counts in the
10 images were used to calculate the axon density per
square millimeter of the optic nerve (ON). Individuals
blinded to the experimental groups performed all axon
counts.
Immunohistochemistry-retinal flat mount
Immediately following euthanasia, eyes were enucleated
and fixed in 4% paraformaldehyde for 2 h at room
temperature. The retina was detached from the eyecup,
and four radial incisions reaching approximately 2/3 of
the radius of the retina were made to create a butterfly
shape. Retinal flatmounts were washed with PBS/T
(0.1% Triton X-100) and permeabilized with 0.1%
Triton X-100 in 20% superblock blocking buffer (2 ml
superblock (Thermo Fisher cat no- 37580) + 8 ml PBS/
T + 10μl Triton X) for 30 min at room temperature.
Following permeabilization, the retinas were blocked in
blocking solution (20% superblock + 10% goat serum)
for 1 h at room temperature. Retinas were then incu-
bated at 4 °C overnight with a primary Ab against
Brn3a, a RGC-specific marker (Millipore Cat no- 1585,
Billerica, MA), or against Iba1, a microglia/macrophage
marker (Wako, Chemicals USA, Inc. Cat# 019-19741).
An Alexa Fluor 555—conjugated for Brn3a— and Alexa
Fluor 488—conjugated for IBA1 (Invitrogen)—was used
as secondary Ab. Nuclei were counterstained with
DAPI (vector stain).
Quantification of retinal ganglion cells
To quantitate retinal ganglion cells, × 60 oil immersion
was used and 16 non-overlapping images were taken (4–5
images per quadrant) using the × 60 oil immersion object-
ive of Leica TCS SP5 confocal microscope system. All
Brn3a-stained RGCs were quantitated using an automated
counting platform we previously developed using CellPro-
filer software [37]. ImageJ software was used to calculate
the area of each image, and the average number of RGCs
in the 16 images was used to calculate the RGC density
per square millimeter of retina. Individuals blinded to the
experimental groups performed all RGC counts.
Quantification of retinal microglia
To quantitate Iba1+ microglia/macrophages, image
stacks of retinal flatmounts were acquired using the ×
20 oil immersion objective (zoom 1.7, 35 μm depth
(includes GCL and IPL)) of the Leica TCS SP5 con-
focal microscope system. The retina was divided into
four quadrants, and one mid-peripheral region was
imaged per quadrant for a total of four images per
retina (480 μm by 480 μm per region). Microglial cells
were counted manually by an individual blinded to the
treatment groups using ImageJ software as previously
described [38]. The longest cell process length, which
is a marker of cell quiescence, was used as a morpho-
metric descriptor to analyze microglia activation using
NeruonJ Fiji Plugin as previously described [39].
Individuals blinded to the experimental groups per-
formed all microglia quantification.
Quantitative RT-PCR
RNA was isolated from the neural retina using a
QIAGEN RNeasy Mini Kit (catalog number 74104),
according to the manufacturer’s protocol. RNA was
treated with DNase (catalog number AM222; Invitro-
gen) to ensure no contamination of genomic DNA.
A total of 500 ng of RNA was reverse-transcribed
(Thermo fisher Cat no 11756050 Superscript IV
VILO master mix) according to the manufacturer’s
instructions. cDNA was diluted 1:4 and then used
for each amplification reaction. cDNA was treated
with RNase H (18021-014; Invitrogen) to ensure the
absence of ssRNA. Quantitative PCR (qPCR) reac-
tions were performed in a 10 μl total volume using
the FastStart Universal SYBR Green Master (Rox)
(4913914001; Sigma) according to the manufacturer’s
protocol. PCR cycles consisted of a denaturation step
at 95 °C for 10 min, followed by 50 cycles of 95 °C
for 15 s and 60 °C for 60 s. Each sample was sub-
jected to melting curve analysis to confirm amplifica-
tion specificity. Samples were run in duplicate, and
each experiment included nontemplate control wells.
Samples were normalized to house-keeping genes
and expressed as the relative expression using the δ-
delta Ct method. Relative expression to two house-
keeping genes β2 microglobulin and PPIA was quan-
tified using the formula: relative expression δ-delta
CT = 2^(avg. gene cT−avg. saline-treated cT). Fold
changes were calculated with respect to saline-
injected control eyes. All of the primers used are
listed in Table 1.
Survival assay
The ability of ONL1204 to inhibit FasL-mediated apoptosis
of murine A20 B lymphoma cells was evaluated in vitro.
Microvesicle preparations were isolated from transfected
Neuro2a cells that expressed either murine mFasL (mFasL
VP) or the vector control (Neo VP) as described previously
[40]. A20 lymphoma cells were incubated for 4 h with titra-
tions of ONL 1204 or the vehicle control together with a 1:
100 dilution of either mFasL VP or Neo VP and then cul-
tured overnight in the presence of 3H-thymidine. Survival
was assessed by 3H-thymidine incorporation using the
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formula (cpm of mFasL VP +ONL1204 or vehicle)/cpm
Neo VP +ONL1204 or vehicle).
Statistics
Graph Pad Prism 8 (La Jolla, CA, USA) was used to per-
form statistical analysis of the data. For the A20 in vitro
study, one-way ANOVA and Dunnett’s multiple com-
parisons test were used to compare different treatment
groups. One-way ANOVA and Dunnett’s multiple com-
parisons test were used for RGC, axon, microglia, and
qPCR analyses. Two-way ANOVA and Dunnett’s mul-
tiple comparisons test were used for all IOP compari-
sons. A P value of less than 0.05 was considered
significant.
Results
ONL1204 blocks FasL-induced apoptosis of Fas+ targets
We previously demonstrated that a small peptide antag-
onist of the Fas receptor (Met12) inhibits Fas-induced
Caspase 8 activation and cell death of photoreceptors
and retinal pigment epithelial cells in models of retinal
detachment and NaIO3 model of oxidative stress re-
spectively [34, 35]. In this study, we used a new deriva-
tive of Met12, ONL1204, with improved pharmaceutical
properties. To confirm that ONL1204 blocks Fas death
receptor signaling, we treated Fas+ murine A20 B
lymphoma cells with membrane-FasL-expressing micro-
vesicles in the presence of increasing concentrations of
ONL1204 (Fig. 1). We previously demonstrated that
microvesicles isolated from transfected Neuro2a cells ex-
pressing murine membrane-bound FasL (mFasL-VP) can
serve as a cell-free source of mFasL that is highly effi-
cient in killing Fas+ murine A20 B lymphoma cells [40].
Microvesicles isolated from Neuro2a cells transfected
with the vector control (Neo-VP) do not express mFasL
and serve as a negative control. Herein, A20 cells were
treated with mFasL-VP at a 1:100 dilution for 4 h, and
3H-Thymidine incorporation indicated significant cell
death with only 8.0% survival when compared to A20
cells incubated with media alone (Fig. 1). By contrast, no
significant cell death was observed in A20 cells treated
with Neo-VP, resulting in 100% survival when compared
to A20 cells incubated with media alone. To determine
whether ONL1204 could block apoptosis triggered by
mFasL-VP, A20 cells were treated with mFasL-VP at a 1:
100 dilution for 4 h in the presence of increasing con-
centrations of ONL1204 or vehicle control. Our results
showed that FasL-induced apoptosis was inhibited by
ONL1204 in a dose-dependent manner, while vehicle
only had no effect (Fig. 1). These results demonstrate
that ONL1204 can block activation of the Fas death re-
ceptor signaling pathway and prevent mFasL-induced
apoptosis.
Fas activation is required for death of RGCs and axon
degeneration in an inducible mouse model of glaucoma
Using genetically modified mice, we demonstrated previ-
ously that the membrane-bound form of FasL (mFasL) is
neurotoxic and accelerates RGC death and axon degener-
ation in inducible and chronic mouse models of glaucoma
[31, 36]. By contrast, overexpression of the soluble form of
FasL (sFasL) via AAV-mediated gene delivery prevented
Table 1 RNA primers used for qPCR
Primers Forward sequence (5′-3′) Reverse sequence (5′-3′)
B2Micr ACGTAACACAGTTCCACCCG CGGCCATACTGGCATGCTTA
Ppia GAGCTGTTTGCAGACAAAGTTC CCCTGGCACATGAATCCTGG
C1Q CAAGGACTGAAGGGCGTGAA CAAGCGTCATTGGGTTCTGC
C3 AGCAGGTCATCAAGTCAGGC GATGTAGCTGGTGTTGGGCT
Casp 8 CTCCGAAAAATGAAG GACAGA CGTGGGATAGGATACAGCAGA
GFAP CCCTGGCTCGTGTGGATTT GACCGATACCACTCCTCTGTC
IL-1β GAAATGCCACCTTTTGACAGTG TGGATGCTCTCATCAGGACAG
IL-6 GTCCGGAGAGGAGACTTCAC CTGCAAGTGCATCATCGTTGT
IL-18 AGTGAACCCCAGACCAGACT TCAGGTGGATCCATTTCCTCAA
IP-10 TGAGCTAGGGAGGACAAGGA GGA TGG CTG TCC TAG CTC TG
MCP1 GGCGGTCAAAAAGTTTGCCT TTCTTCCGTTGAGGGACAGC
MIP-1α TGCCAAGTAGCCACATCGAG TGACCAACTGGGAGGGAGAT
MIP-1β GTCCTTGCTCCTCACGTTCA CCATCTCCATGGGAGACACG
MIP-2 GGCGGTCAAAAAGTTTGCCT TTCTTCCGTTGAGGGACAGC
NLRP 3 ATTACCCGCCCGAGAAAGG TCGCAGCAAAGATCCACACAG
TLR4 CTCTGGGGAGGCACATCTTC CCCAGGTGAGCTGTAGCAT
TNF-α CCTCTCATGCACCACCATCA GCATTGCACCTCAGGGAAGA
Krishnan et al. Journal of Neuroinflammation          (2019) 16:184 Page 5 of 15
RGC death and axon degeneration [31]. While these previ-
ous studies revealed opposing roles for mFasL and sFasL in
the pathogenesis of glaucoma, the requirement of the Fas
signaling pathway for the development of glaucoma was
never demonstrated. Therefore, to determine whether Fas
signaling was required for the development of glaucoma, we
utilized a well-defined microbead-induced mouse model of
elevated IOP to induce elevated IOP in C57BL/6J WT mice
and Fas-deficient LPR mice (Faslpr)) [41]. As previously de-
scribed [31], a single anterior chamber injection of 15 μm
polystyrene microbeads resulted in elevated IOP for up to
21 days in C57BL/6J WT as compared to saline controls
(Fig. 2a). The IOP was monitored by rebound tonometry,
and there was no significant difference in the time course or
magnitude of the microbead-induced elevated IOP between
Faslpr mice or C57BL/6J WT mice, indicating Fas signaling
was not involved in the elevation of IOP. At 4weeks post-
microbead injection, RGC density was measured in retinal
whole mounts stained with a RGC-specific anti-Brn3a anti-
body [37] (Fig. 2b, c) and axon density was measured in
optic nerve sections stained with PPD [31] (Fig. 2d, e).
Quantification of RGCs revealed a significant decrease in
RGC density in microbead-injected WT mice as compared
to saline-injected controls (Fig. 2c). However, in the absence
of Fas signaling, the RGC density in microbead-injected
Faslpr mice was equal to that of saline-injected controls
(Fig. 2c). Similar results were observed in the optic nerve
where Fas deficiency afforded complete protection of axons
in microbead-injected Faslpr mice as compared to the
microbead-injected C57BL/6 WT mice (Fig. 2d, e). Taken
together, these results demonstrate that Fas signaling is re-
quired for the death of RGCs and loss of axons in the
microbead-induced mouse model of glaucoma.
Pre-elevated IOP treatment with ONL1204 protects RGCs
and prevents axon degeneration in the microbead-
induced model of glaucoma
To determine the neuroprotective potential of Fas-
receptor inhibition in glaucoma, we pretreated C57BL/
6J WT mice with ONL1204, prior to induction of ele-
vated IOP. In this study, C57BL/6J WT mice received
an intravitreal injection of ONL1204 (2 μg/μl) or
vehicle only, immediately preceding injection of
microbeads or saline. IOPs were monitored every 3–4
days by rebound tonometry and revealed no significant
difference in the time course or magnitude of the
microbead-induced elevated IOP between mice treated
with ONL1204 or vehicle only, indicating ONL1204
did not affect IOP (Fig. 3a). Quantification of RGCs at
4 weeks post-microbead injection revealed a signifi-
cant decrease in RGC density in microbead-injected
vehicle-treated mice as compared to the saline-
injected controls (Fig. 3b, c). However, pretreatment
with ONL1204 was neuroprotective, and the RGC
density in microbead-injected ONL1204-treated mice
was equal to the RGC density in the saline-injected
controls (Fig. 3b, c). Similar results were observed in
the optic nerve with a significant decrease in axon
Fig. 1 ONL1204 rescues A20 B lymphoma cells from FasL-mediated apoptosis. The ability of ONL1204 to inhibit FasL-mediated apoptosis of
murine A20 B lymphoma cells was evaluated in vitro. Microvesicle preparations were isolated from transfected Neuro2a cells that expressed either
murine mFasL (mFasL VP) or the vector control (Neo VP) as described previously [40]. A20 lymphoma cells were incubated for 4 h with increasing
concentrations of ONL1204 or the vehicle control together with a 1:100 dilution of either mFasL VP or Neo VP and then cultured overnight in the
presence of 3H-thymidine. Percent survival was assessed by 3H-thymidine incorporation using the formula (cpm of A20 cells cultured with mFasL
VP + ONL1204 or vehicle)/(cpm of A20 cells incubated with media alone). A20 cells cultured with mFasL-VP alone served as the positive control
(≈ 8% survival), while A20 cells cultured with neo-VP alone served as the negative control (≈ 100% survival). Data presented as % survival ± SEM.
N = 6 per group, ***P < 0.001, ****P < 0.0001
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density detected in microbead-injected, vehicle-treated
mice when compared to saline-injected controls, while
pretreatment with ONL1204 afforded complete pro-
tection of axons with axon density in microbead-
injected ONL1204-treated mice equal to that of the
saline-injected controls (Fig. 3d, e). Taken together,
these results demonstrate that pretreatment with the
Fas inhibitor, ONL1204, prior to elevated IOP pro-
vides significant neuroprotection to both RGCs and
their axons in the microbead-induced mouse model of
glaucoma.
Post-elevated IOP treatment with ONL1204 protects RGCs
and prevents axon degeneration in the microbead-
induced model of glaucoma
While pretreatment with ONL1204 provided signifi-
cant neuroprotection in the microbead-induced mouse
model of glaucoma, the more clinically relevant ques-
tion is whether treatment with ON1204 can provide
neuroprotection even when administered after detec-
tion of elevated IOP, as this would be the time at
which glaucoma patients would most likely receive
treatment. To answer this question, C57BL/6J WT
mice received an anterior chamber injection of
microbeads or saline, and at 7 days post-microbead
injection, all mice receive an intravitreal injection of
ONL1204 or vehicle alone. IOPs were monitored
every 3–4 days by rebound tonometry, verifying that
IOP was elevated prior to intravitreal injection of the
drug or vehicle. The IOP data revealed no significant
difference in the time course or magnitude of the
IOP between mice treated with ONL1204 or vehicle
at 7 days post-microbead injection (Fig. 4a). At 4
weeks post-microbead injection, quantification of
RGCs revealed significant preservation of RGCs in the
ONL1204-treated mice when compared to mice
treated with vehicle alone (Fig. 4b, c). Significant pro-
tection of axons was also observed with axon density
in ONL1204-treated mice equivalent to the axon
density in saline-treated controls (Fig. 4d, e). In con-
clusion, these data demonstrate that inhibition of Fas
activation provides significant protection to both the
RGCs and axons, even when administered after ele-
vated IOP.
Fig. 2 Fas signaling pathway is required for death of RGCs and loss of axons in microbead-induced model of glaucoma. a IOP measurements
were taken by rebound tonometry in WT and Fas-deficient Faslpr mice injected with microbeads or saline. Data is presented as mean IOP ± SD,
N = 6 mice per group. IOP was significantly elevated on days 3–21 in WT and LPR mice that received microbeads as compared with WT control
mice receiving saline (****P < 0.0001). b Representative confocal images of retinal flatmounts isolated at 28 days post-microbead or saline
injection and stained with an anti-Brn3a antibody (red, RGC-specific marker) and a DAPI nuclear stain (blue) (scale bar, 50 μm). c Quantification of
Brn3a positive RGCs represented as the mean RGC density/mm2 retina ± SD. N = 6 per group, ***P<0.001, **P<0.01. d Representative
photomicrographs of PPD-stained optic nerve cross-sections at 28 days post-microbead or saline injections (scale bar, 20 μm). e Quantification of
healthy axons represented as the mean axon density (104)/mm2 ON ± SD. N = 6 per group, ****P < 0.0001
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ONL1204-mediated neuroprotection correlates with
reduced activation of Iba1+ microglia and/or infiltrating
macrophages
In human and experimental models of glaucoma, activated
microglia are detected in the optic nerve head and retina
[14–19], and blocking microglia activation with minocy-
cline [14, 20], anti-TNF [22, 23], or irradiation [42] prevents
death of RGCs and axon degeneration. While triggering the
Fas receptor is best known for inducing apoptosis, we pre-
viously demonstrated that accelerated death of RGCs in
mice that only express the membrane form of FasL (mFasL)
correlated with increased activation of retinal microglia,
suggesting that FasL mediates both RGC apoptosis and glial
activation [36]. To determine whether ONL1204-mediated
neuroprotection correlates with inhibition of microglia acti-
vation in the neural retina, C57BL/6J WT mice were pre-
treated with ONL1204 just prior to the anterior chamber
injection of microbeads. At 28 days post-microbead injec-
tion, retinal whole mounts were stained with Iba1 (micro-
glia/macrophage marker). Retinal microglia are located in
the ganglion cell layer (GCL), inner plexiform layer (IPL),
and outer plexiform layer (OPL). However, we did not de-
tect any changes in the microglia in the OPL during the
development of glaucoma in our model system, and since
glaucoma specifically targets the RGCs and their axons, we
focused our analysis on microglia in the GCL and IPL of
the retina. Representative confocal images from saline
control groups treated with vehicle or ONL1204 reveal
Iba1+ cells with a quiescent phenotype and dendritic
morphology (Fig. 5a), while confocal images from
microbead-injected mice treated with vehicle only reveal
Iba1+ cells with an activated phenotype and amoeboid
morphology (Fig. 5a). By contrast, the Iba1+ cells in retinal
whole mounts prepared from microbead-injected mice pre-
treated with ONL1204 maintained a quiescent phenotype
with dendritic morphology, similar to that observed in the
saline-injected control groups (Fig. 5a). Quantification of
microglia density in the GCL/IPL revealed no significant
difference in absolute number of Iba1+ cells at 28 days
post-microbead injection between all groups (Fig. 5b).
However, quantification of microglia activation, using the
measurement of the longest process length as previously
described [39], revealed a significant shortening of the cell
process length in Iba1+ cells from microbead-injected mice
treated with vehicle as compared to Iba1+ cells from
microbead-injected mice treated with ONL1204 (Fig. 5c).
These data indicate that Fas activation mediates both RGC
apoptosis and microglia activation.
ONL1204-mediated neuroprotection correlates with a
significant reduction in inflammatory cytokines and
chemokines
In human and experimental glaucoma, multiple inflamma-
tory pathways have been implicated in the pathogenesis of
Fig. 3 Pre-elevated IOP treatment with ONL1204 protects RGCs and prevents axon degeneration in microbead-induced model of glaucoma. WT
C57BL/6J mice received an intravitreal injection of ONL1204 (2 μg/1 μl injection) or vehicle only, immediately followed by an anterior chamber
injection of microbeads or saline (day 0). a IOP measurements were taken by rebound tonometry every 3–4 days. Data is presented as mean
IOP ± SD, N = 8 mice per group. IOP was significantly elevated on days 3–21 in microbead-injected WT mice treated with ONL1204 or vehicle
when compared to saline-injected WT controls treated with ONL1204 or vehicle (****P < 0.0001). b Representative confocal images of retinal
flatmounts isolated at 28 days post-microbead or saline injection and stained with an anti-Brn3a antibody (red, an RGC-specific marker) and a
DAPI nuclear stain (blue) (scale bar, 50 μm). c Quantification of Brn3a-positive RGCs represented as the mean RGC density/mm2 retina ± SD. N = 8
per group, ***P < 0.001, ****P < 0.0001. d Representative photomicrographs of PPD-stained optic nerve cross-sections at 28 days post-microbead
or saline injections (scale bar, 20 μm). e Quantification of healthy axons represented as the mean axon density (104)/mm2 ON ± SD. N = 8 per
group, ***P < 0.001, ****P < 0.0001
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disease, including the Toll-like receptor signaling pathway
[43], the inflammasome pathway [44–47], the TNFα
pathway [22, 23, 48–50], and the complement cascade
[51–53]. While triggering of the Fas receptor is best
known for inducing apoptosis through the activation of
caspase-8, activated caspase-8 can also induce the produc-
tion of pro-inflammatory mediators [54–57]. Moreover,
caspase-8 activation has also been linked to microglia acti-
vation [58] and inflammation in experimental models of
glaucoma and inhibiting caspase-8 blocked inflammation
and prevented death of RGCs [45]. To explore the role of
Fas activation in triggering inflammation in glaucoma, we
pretreated C57BL/6J WT mice with ONL1204 just prior
to injection of microbeads, and at 28 days post-microbead
injection, the neural retina was isolated, and qPCR was
performed to assess the expression of several proinflam-
matory genes associated with human and/or experimental
models of glaucoma. We first examined the gene expres-
sion of caspase-8, which plays an essential role in Fas re-
ceptor signaling cascades that induces both apoptosis and
cytokine production [55], as well as GFAP as a measure of
glial activation. The qPCR analysis revealed a significant
induction in both GFAP and Caspase-8 in microbead-
injected mice treated with vehicle only, as compared to
saline-treated controls (Fig. 6a). We then examined the
gene expression of several proinflammatory cytokines
(TNFα, IL-1β, IL-6, and IL-18) (Fig. 6b) and chemokines
(MIP-1α, MIP-1β, MIP-2, MCPI, and IP10) (Fig. 6c) that
have been implicated in human and experimental models
of glaucoma [43, 48, 59–61]. The qPCR analysis revealed
significant induction of each of these genes in the retina of
microbead-injected mice treated with vehicle only as
compared to the saline-treated controls (Fig. 6b, c). By
contrast, pretreatment with ONL1204 prevented the in-
duction of each of these genes and gene expression was
equivalent to the saline-treated control (Fig. 6b, c).
Additionally, key mediators of the Toll-like receptor path-
way, inflammasome pathway, and complement cascade
that have been identified in human and experimental glau-
coma were also examined, specifically TLR4 [43, 44],
NLRP3 [44, 45, 48], and complement components C3 and
C1Q [53, 62, 63]. Similar to the proinflammatory cyto-
kines and chemokines, gene expressions of C3, C1Q,
TLR4, and NLRP3 were all significantly induced at 28 days
post-microbead injection in the retina of microbead-
injected mice treated with vehicle only as compared to
saline-treated controls (Fig. 6d, e). However, the induction
of each of these genes was inhibited in microbead-injected
mice that were pretreated with ONL1204 (Fig. 6d, e).
Together, these results suggest that Fas activation is
upstream to multiple inflammatory pathways that have
been implicated in glaucoma and blocking Fas activation
Fig. 4 Post-elevated IOP treatment with ONL1204 protects RGCs and prevents axon degeneration in microbead-induced model of glaucoma. WT
C57BL/6J mice received an intravitreal injection of ONL1204 (2 μg/1 μl injection) or vehicle at 7 days post-anterior chamber injection of
microbeads or saline. a IOP measurements were taken by rebound tonometry every 3–4 days. Data is presented as mean IOP ± SD, N = 6 mice
per group. IOP was significantly elevated on days 3–21 in microbead-injected WT mice treated with ONL1204 or vehicle when compared to
saline-injected WT controls treated with ONL1204 or vehicle (****P < 0.0001). b Representative confocal images of retinal flatmounts isolated at
28 days post-microbead or saline injection and stained with an anti-Brn3a antibody (red, an RGC-specific marker) and a DAPI nuclear stain (blue)
(scale bar, 50 μm). c Quantification of Brn3a-positive RGCs represented as the mean RGC density/mm2 retina ± SD. N = 6 per group (***P < 0.001,
****P < 0.0001). d Representative photomicrographs of PPD-stained optic nerve cross-sections at 28 days post-microbead or saline injections (scale
bar, 20 μm). e Quantification of healthy axons represented as the mean axon density (104)/mm2 ON ± SD. N = 6 per group, **P < 0.01
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with ONL1204 prevents RGC apoptosis, as well as micro-
glia activation and the induction of neurodestructive
inflammation.
Discussion
In this study, we evaluated the neuroprotective effect
of ONL1204, a novel small peptide inhibitor of the Fas
receptor, in a microbead-induced mouse model of ele-
vated IOP. We previously demonstrated that apoptosis
of RGCs in both inducible and chronic mouse models
of glaucoma was dependent upon the FasL-Fas signal-
ing pathway [31, 36]. While several studies have impli-
cated the proinflammatory cytokine TNFα as the
critical link between elevated IOP and death of RGCs
in glaucoma [22, 23, 48, 49], Nakazawa et al. demon-
strated in a laser-induced mouse model of ocular
hypertension that TNFα does not directly kill RGCs,
but rather RGC death is dependent upon TNFR2-
mediated activation of microglia [23]. Our laboratory
went on to demonstrate that TNFα increased expres-
sion of FasL on microglia in the glaucomatous retina
and that the membrane-bound form of FasL was the
key effector of RGC apoptosis in an inducible mouse
model of glaucoma [36]. However, it has become
increasingly apparent that in addition to apoptosis,
Fas-mediated signaling can also induce the release of
proinflammatory cytokines and promote inflammation
[40, 64–66]. Using our novel Fas inhibitor, ONL1204,
in an inducible mouse model of glaucoma, we show
that blocking Fas activation prevents axon degener-
ation and the death of RGCs, as well as the activation
of microglia and the induction of multiple inflamma-
tory genes previously implicated in both experimental
and human glaucoma. Importantly, many of the cyto-
kines and chemokines we have now quantified in the
glaucomatous eyes are the same proinflammatory mol-
ecules that we previously found to be produced by
FasL-treated macrophages [40]. Moreover, the data
presented herein provide proof of principle that treat-
ment with ONL1204 effectively blocks Fas activation
and affords significant neuroprotection to RGCs and
their axons in an experimental model of glaucoma.
Having identified the FasL-Fas signaling pathway as an
essential pathway in the pathogenesis of glaucoma, the
first aim of the present study was to evaluate the
neuroprotective effect of our novel Fas inhibitor,
ONL1204, in the microbead-induced mouse model of
glaucoma. The ONL1204 inhibitor is a new derivative
of Met12, a small peptide that we showed could in-
hibit Fas activation and subsequent apoptosis of pho-
toreceptors and retinal pigment epithelial cells in
models of retinal detachment and retinal degeneration
Fig. 5 Inhibition of Fas signaling prevents activation of retinal microglia following elevated IOP. WT C57BL/6J mice received an intravitreal
injection of ONL1204 (2 μg/1 μl injection) or vehicle just prior to an anterior chamber injection of microbeads or saline (day 0). a Representative
confocal images of retinal flatmounts isolated at 28 days post-microbead or saline injection and stained with an anti-Iba1 antibody (red,
microglia/macrophage marker). Iba1+ cells in the saline-injected WT mice treated with vehicle or ONL1204 displayed a quiescent phenotype with
dendritic morphology (white arrow), while Iba1+ cells in microbead-injected WT mice treated with vehicle display a more activated phenotype,
with amoeboid morphology (white arrowhead) that is inhibited in microbead-injected mice treated with ONL1204 (scale bar, 50 μm). b
Quantification of Iba1+ cells in the GCL/IPL revealed no significant difference between any groups at 28 days post-microbead injection. c
Morphometric analysis was performed on Iba1+ cells in the GCL/IPL (60 cells per retina), and the longest process length measured from the edge
of the cell body (in micrometer) was used to quantitate microglia activation as previously described. Data presented as the mean microglia
density/mm2 ± SD and the mean longest process length in μM ± SD. N = 3–4 per group, ***P < 0.001, ****P < 0.0001
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[34, 35]. Through assessment of axon degeneration
and RGC survival, our results provide proof-of-
principal that ONL1204 can provide robust neuropro-
tection in an inducible mouse model of glaucoma,
even when administered after the detection of elevated
IOP. In addition, we found that ONL1204-mediated
neuroprotection correlates with significantly reduced
activation of retinal microglia and no significant in-
duction of proinflammatory genes implicated in both
human and experimental glaucoma. These data sup-
port our hypothesis that in glaucoma, Fas activation is
a critical mediator of RGC apoptosis, as well as micro-
glial activation and neuroinflammation.
The results of this present study are in agreement with
our previous work using an AAV2-mediated gene ther-
apy approach to deliver soluble FasL, considered an an-
tagonist of the proapoptotic and proinflammatory
membrane form of FasL [31]. Overexpression of sFasL
using the AAV2-mediated gene therapy approach pre-
vented axon degeneration and death of RGCs in both in-
ducible and chronic mouse models of glaucoma, and
this neuroprotection correlated with an inhibition of
Müller glia activation and induction of inflammatory
mediators [31]. Taken together, the previous results of
our sFasL-AAV2 study combined with results of the
present study with ONL1204 strongly support the value
Fig. 6 Inhibition of Fas signaling prevents the induction of multiple inflammatory pathways implicated in the pathogenesis of glaucoma. At 28
days post-microbead or saline injection, quantitative PCR was performed on neural retina isolated from saline- and microbead-injected WT mice
treated (on day 0) with ONL1204 or vehicle to assess the expression of several proinflammatory genes associated with human and/or
experimental models of glaucoma: a Caspase 8 and GFAP, b proinflammatory cytokines (TNFα, IL-1β, IL-18, and IL-6), c proinflammatory
chemokines (MIP-1α, MIP-1β, MIP-2, MCPI, and IP10), d complement components C3 and C1Q, and e NLRP3 and TLR4. The threshold cycle values
of each gene of interest were normalized to the geometric mean of two housekeeping genes (B2-microglobulin and peptidylpropyl isomerase A)
and compared with the saline + vehicle control group using the comparative C method (ΔΔC). Data are presented as fold change of control ±
SEM. N = 6 per group, *P < 0.05, **P < 0.01, ***P < 0,001, ****P < 0.0001
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of Fas inhibition as an approach to neuroprotection in
glaucoma, both in preserving RGC viability and in pre-
venting neuroinflammation.
Neuroinflammation has long been associated with
chronic neurodegenerative diseases such as Alzheimer’s
and Parkinson’s [67–69]. However, while glial activation
and inflammatory cytokines have been detected in the
optic nerve head and retina of human [17, 19, 48] and
experimental models of glaucoma [20, 21, 60, 70], the
specific impact of glial activation and neuroinflammation
on the development and/or progression of glaucoma is
not well understood. In human and experimental models
of glaucoma, activated microglia are detected in the
ONH and retina [14, 16, 17, 19, 20]. Microglia are the
resident innate immune cells of the retina and optic
nerve and are responsible for normal maintenance of
neuronal tissue, as well as a local response to injury.
However, in retinal degenerative diseases, chronic
microglia activation has been linked to retinal damage
and neuronal apoptosis [71] and the extent of microglia
activation in the ONH coincides with the severity of
axon degeneration [14, 20, 21]. Moreover, Barres and
colleagues demonstrate in the CNS that neurotoxic as-
trocytes are induced by activated microglia [72] and
blocking microglial activation with minocycline [14, 20]
or anti-TNF [22, 23] prevents axon degeneration and
death of RGCs suggesting that activated microglia are
the driving force behind the axon degeneration and
death of RGCs in glaucoma. However, the molecular
mechanism(s) that mediate microglia reactivity in glau-
coma have not yet been defined.
While the specific trigger(s) of neuroinflammation in
glaucoma remains poorly defined, a number of key in-
flammatory pathways have been implicated in the patho-
genesis of glaucoma and are common to both human
and animal models of glaucoma. These pathways include
the complement cascade [53, 62, 63], Toll-like receptor
pathway [43, 44], TNFα pathway [22, 23, 48–50], and
inflammasome pathway [44–47]. Using the microbead-
induced mouse model of glaucoma, we also show an in-
duction of genes associated with each of these pathways
at 4 weeks post-microbead injection, specifically C3 and
C1Q (complement cascade), TLR4 (Toll-like receptor
pathway), TNFα (TNFα pathway), and NLRP3 (inflam-
masome pathway). However, treatment with ONL1204
completely abrogated the induction of each of these
genes, indicating that Fas activation is upstream to these
pathways and plays a central role in mediating neuroin-
flammation in glaucoma. In addition, the induction of
these inflammatory genes correlated with a significant
increase in the number of activated, amoeboid-shaped
Iba1+ cells in the retina and treatment with ONL1204
completely abrogated the activation of Iba1+ cells in the
retina with the Iba1+ cells displaying a homeostatic,
dendritic phenotype indistinguishable from the non-
glaucoma controls. Together, these data indicate that
blocking Fas signaling prevents microglial activation and
the development of neuroinflammation.
However, the Fas receptor is expressed on multiple ret-
inal cell types, including astrocytes, RGCs, Mueller cells,
microglia, and retinal pigment epithelial cells [7, 31, 36, 73].
Therefore, additional studies in which the Fas receptor is
deleted from specific cell types will be necessary to deter-
mine which Fas receptor-positive cell(s) actually drive(s)
the development of neuroinflammation in glaucoma. More-
over, Fas mediates both apoptotic and inflammatory path-
ways and it is not possible from the current studies to
determine the extent to which Fas-mediated apoptosis and/
or Fas-mediated inflammation contributes to axon degener-
ation and death of RGCs in glaucoma. Yet, previous thera-
peutic approaches that specifically targeted the apoptotic
pathway alone resulted in neuroprotection of the RGC
soma but failed to prevent axon degeneration [11, 12], sug-
gesting the robust neuroprotective effect afforded by
ONL1204 is dependent upon the ability of ONL1204 to
antagonize both Fas-mediated apoptosis of RGCs and Fas-
mediated activation of retinal microglia and induction of
neuroinflammation. Additional studies in which the Fas re-
ceptor is specifically knocked out in RGCs or glial cells
(microglia, astrocytes, and Mueller cells) are necessary to
determine if the neuroprotective effects of ONL1204 are
mainly driven by modulating the inflammatory response of
retinal glial cells or preventing FasL-induced apoptosis of
RGCs.
While triggering of the Fas receptor is known for
inducing apoptosis through the activation of caspase-8,
activated caspase-8 can also induce the production of pro-
inflammatory mediators [44, 55, 57, 74]. Although
activation of IL-1β and IL-18 is most often thought to be
inflammasome-dependent, we recently demonstrated that
Fas can mediate IL-1β and IL-18 maturation via a
caspase-8-dependent inflammasome-independent mech-
anism [55]. In addition, caspase-8 activation has been
linked to inflammation in experimental models of glau-
coma and inhibition of caspase-8 blocks inflammation and
prevents death of RGCs [44, 45]. Yet, similar to our
findings presented herein, the previous caspase-8 studies
were unable to determine the extent to which caspase-8-
mediated inflammation and/or caspase-8-mediated apop-
tosis contributed to axon degeneration and RGC apop-
tosis. However, while caspase-8-mediated inflammation
can be triggered by the Fas-receptor [55, 74], TRAIL re-
ceptor [75], and Toll-like receptors (TLRs) [76, 77], we
demonstrate herein that specifically blocking Fas activa-
tion in the microbead-induced mouse model of glaucoma
inhibits the induction of caspase-8, retinal microglia
activation, and the induction of proinflammatory genes,
indicating the TRAIL- and TLR-mediated pathways are
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downstream of the FasL-Fas pathway. Moreover, deter-
mining the extent to which Fas-mediated inflammation
and/or apoptosis contributes to axon degeneration and
death of RGCs in glaucoma will require the uncoupling
the Fas-mediated apoptosis and Fas-mediated inflamma-
tory pathways and this will be the focus of our future
studies.
As a complex multifactorial disease, we predict the most
successful neuroprotective therapy for glaucoma will have
to impact multiple pathways and the data presented herein
strongly support pursuing the FasL-Fas signaling pathway
as an optimal target for successful neuroprotection in glau-
coma. Specifically blocking Fas activation in this present
study resulted in significant inhibition of glial activation,
neuroinflammation, and RGC death. In the normal eye, the
FasL-Fas signaling pathway plays an essential role in the
maintenance of ocular immune privilege where inflamma-
tion is tightly regulated [28, 78, 79]. However, it has become
increasingly clear that immune privilege is not simply
established through suppression of all immune responses,
but rather through modulation of the immune responses in
a way that provides immune protection to the delicate
tissues of the eye while limiting the development of de-
structive inflammation. FasL is constitutively expressed in
the immune-privileged eye where the membrane form of
FasL is the active form, inducing apoptosis of infiltrating
Fas+ immune cells [28, 78, 79]. However, because the Fas
receptor is ubiquitously expressed on multiple cell types
throughout the eye, the cleavage or shedding of mFasL acts
to limit the expression of mFasL and prevent the killing of
healthy Fas+ bystander cells [80, 81]. However, in glau-
coma, the cleavage or shedding of mFasL is significantly re-
duced resulting in a significant decrease in release of sFasL
and concomitant increase in the expression of mFasL that
correlates with the apoptosis of Fas+ RGCs [31]. Therefore,
we propose that either treatment with sFasL, as we previ-
ously demonstrated [31], or treatment with a Fas inhibitor
as shown in this present study will work to (i) block the
proapoptotic and proinflammatory activity of mFasL, (ii)
promote restoration of the ocular immune-privileged envir-
onment, and (iii) support the return of the activated retinal
microglia to their original homeostatic phenotype.
Conclusions
In summary, our data provide proof-of-principal that
treatment with the small peptide inhibitor of the Fas
receptor, ONL1204, provides significant protection of
the RGC soma and their axons in an inducible mouse
model of glaucoma. In addition, the studies presented
herein demonstrate the requirement of Fas activation
in both the death of RGCs and axon degeneration, as
well as the activation of retinal microglial and induc-
tion of neuroinflammation in the development of
glaucoma. Future studies will be aimed at identifying
the critical source of FasL and uncoupling the Fas-
mediated apoptosis and Fas-mediated inflammatory
pathways in order to determine the extent to which
inflammation versus apoptosis contributes to the de-
velopment and progression of glaucoma.
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